| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 46.05 | 0.00 (0.00%) | 30.64 - 49.57 | 38.9 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 46.05 |
| Day's Range | -- - -- |
| Market Cap | 75.6B |
| Avg Volume (10 Day) | 9.0M |
| Price/Earnings (Trailing 12 Mo.) | 52.9x |
| Earnings Per Share (Trailing 12 Mo.) | 0.87 |
| Dividend Yield | 0.35 (3.04%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Pass |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Bristol-Myers Squibb Names Dinesh C. Paliwal to Board of Directors
Business Wire - Wednesday 06/19/2013 4:31 PM ET
Bristol-Myers Squibb Announces Dividend
Business Wire - Wednesday 06/19/2013 4:30 PM ET
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)
Business Wire - Wednesday 06/19/2013 2:02 AM ET
Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers
Business Wire - Tuesday 06/18/2013 9:00 AM ET
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire - Monday 06/17/2013 8:00 AM ET
Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma
Business Wire - Saturday 06/15/2013 11:45 AM ET
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
Business Wire - Friday 06/14/2013 9:00 AM ET
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
PR Newswire - Friday 06/14/2013 8:00 AM ET
| BMY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -24.59% | |
| Net Income Growth (1yr) | -40.61% | |
| Total Debt/Equity | 0.58 | |
| LT Debt/Equity | 0.48 | |
| Earnings Yield | 1.89% | |
| Price/Sales | 4.67 |
| Company | Last | Change |
|---|---|---|
| AbbVie Inc | 43.04 | 0.00% |
| Eli Lilly and Co | 51.37 | 0.00% |
| GlaxoSmithKline PLC | 51.48 | 0.00% |
| Sanofi SA | 53.40 | 0.00% |
| Merck & Co Inc | 47.58 | 0.00% |
Data is delayed by at least 15 min.